Summary
Coluracetam (BCI-540; formerly MKC-231) is a nootropic belonging to the racetam family of drugs. It was originally developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug had failed to reach the endpoints in its clinical trials, it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings from phase IIa clinical trials have suggested that it would be a possible medication for a comorbid major depressive disorder (MDD) with generalized anxiety disorder (GAD).
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 3-5mg | 5-10mg | 10-20mg | 20mg+ |
| Sublingual | 2-5mg | 5-10mg | 10mg | 10mg+ |
| Insufflated | 2-5mg | 5-10mg | 10-20mg | 20mg+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Peak | Offset | After Effects | Total |
|---|---|---|---|---|---|
| Oral | 15-30 min | 1-2 hrs | 3-5 hrs | 1-6 hrs | 180-0 min |
| Sublingual | 1-5 min | 1-2 hrs | 3-5 hrs | 1-6 hrs | 180-0 min |
| Insufflated | 0-6 min | - | - | 60-0 min | 180-0 min |
Tolerance
Build-up
develops over days to weeks of regular use
Reset
3–7 days for acute tolerance; longer for full reset
Effects
Positive
- Stimulation
- Stamina enhancement
- Mild stimulation
- Creativity enhancement
Negative
- Increased heart rate
- Headaches
- Insomnia
- Headache
- Motor impairment
- Sedation
Positive
- Memory enhancement
- Motivation enhancement
- Thought connectivity
- Anxiety suppression
- Dream potentiation
- Focus enhancement
- Mindfulness
- Wakefulness
- Analysis enhancement
Negative
- Irritability
Positive
- Color enhancement
- Visual acuity enhancement
- Auditory acuity enhancement
- Acuity enhancement
- Auditory enhancement
- Colour enhancement
- Tactile enhancement
- Music enhancement
Negative
- Light sensitivity
- Dulled perception